Vol. 29 No. 02 (2018): JIB

The challenges of pricing innovative drugs

Clinical trials of advanced therapy medicinal products: which future
for the European regulation?'

The moral economy of the availability of therapeutic innovations for neglected
diseases

Risks and benefits of medical nanotechnologies: a balancing to be
Reconsidered

Biosimilars: a regulatory framework at the crossroads of health security
and health economics.

Legal issues and for the health system of the development of a new class
of innovative therapy in oncoimmunology: the “Car-T Cells” .